Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone versus triamcinolone + 5-fluorouracil for keloids and hypertrophic scars
ACTRN12612000546853Phase 4Completed
- Sponsor
- Farrukh Aslam Khalid
- Start
- May 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of triamcinolone acetonide and fluorouracil in keloid and Hypertrophic Scar (HS) (2 arms), sponsored by Farrukh Aslam Khalid. Primary endpoints: Mean reduction in scar height and Efficacy defined by >50% reduction in initial scar height. Started May 2012; status: completed.
02
Drugs
triamcinolone acetonidefluorouracil
03
Conditions
keloidHypertrophic Scar (HS)
Beyond the preview
Go deeper on ACTRN12612000546853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000546853.